Tag: HEMERA-1
Prolong Pharmaceuticals gains US FDA fast-track designation for novel stroke therapy
Prolong Pharmaceuticals has announced that its investigational therapy—PEGylated carboxyhemoglobin, bovine (PP-007)—has received a fast-track designation from the US Food and Drug Administration (FDA) for...
Positive HEMERA-1 data pave the way for further neuroprotection trials during...
Following the recent publication in Stroke: Vascular and Interventional Neurology of results from HEMERA-1, a prospective, multicentre trial evaluating the safety of novel neuroprotective...
LINNC 2023 examines neuroprotection, steerable microcatheters and other ‘next frontiers’
Neuroprotective agents and steerable microcatheter technologies were among a number of potential new interventional neuroradiology (INR) frontiers showcased and discussed at this year’s LINNC...
